NewAmsterdam Pharma (NAMS.US) Announces Phase 2 Trial Results of CETP Inhibitor Under Development Effectively Reduces “Bad Cholesterol” Levels

The Zhitong Finance App learned that recently, NewAmsterdam Pharma (NAMS.US) announced the results of its Phase 2 trial to develop the CETP inhibitor Obicetrapib during the 2024 American College of Cardiology (ACC). Analysis showed that obicetrapib, as a single drug or in combination with ezetimibe, can effectively reduce low density lipoprotein cholesterol (LDL-C) levels in patients with dyslipidemia (dyslipidemia). NewAmsterdam also announced its associated Phase 3 key trial PRE

Zhitong FinanceApr 9 23:20 ET

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients With Established Atherosclerotic Cardiovascular Disease

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS） today announced that it has met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial ("CVOT") evaluating obicetrapib in adult patients with a history of atherosclerotic cardiovascular disease ("ASCVD"), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.

GlobeNewswireApr 9 08:00 ET

Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and NewAmsterdam Pharma Company (NAMS)

TipRanksApr 2 08:30 ET

NewAmsterdam Pharma Announces Executive Leadership Changes

TipRanksApr 1 08:32 ET

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

We are privileged to welcome Juliette to our management team as CBO," said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.

GlobeNewswireApr 1 08:00 ET

Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing

Johannes Jacob Pieter Kastelein, Director, Chief Scientific Officer, on March 26, 2024, sold 190,476 shares in Newamsterdam Pharma (NAMS) for $4,095,234. SEC Filing: https://www.sec.gov/Archives/edgar

MT NewswiresMar 27 16:41 ET